anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Trospium
Trial phase: Phase 2
ATC code: A03DA06 | G04BD09
SMILES: [H][C@]12CC[C@]([H])(C[C@H](OC(=O)C(O)(c3ccccc3)c3ccccc3)C1)[N+]21CCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda

Pegylated interferon lambda: 180 mcg subcutaneous injection of pegylated interferon lambda
Eligibility criteria:
Inclusion Criteria:

Able to provide informed consent
Confirmed COVID-19 diagnosis based on PCR analysis of respiratory secretions
Positive SARS-CoV-2 RT-PCR test must be within 48 hours of randomization

Exclusion Criteria:

Clinically-significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol
Treatment with IFN or other immunomodulatory/immunosuppressive agent within 12 months before screening.
Respiratory compromise requiring ventilatory support other than nasal cannula (mask, bipap or intubation and mechanical ventilation)
History of treatment with any of the following medications within five half-lives or 30 days before administration of the study drug (whichever is longer): anti-IL-6, anti-IL6R antagonists, Janus kinase inhibitors, ustekinumab (anti-IL-12/23), or anti IL-23 agents (guselkumab).
Life threatening SAE during the screening period
Pregnant or Nursing Females
Platelet count <90,000 cells/mm3
WBC count <3,000 cells/mm3
ANC <1,500 cells/mm3
Hb <11 g/dL for women and <12 g/dL for men
CrCl < 50 mL/min
Bilirubin level ≥ 1.5x ULN
INR ≥1.5 (except in the setting of concomitant anticoagulant use)
CRP > 200 mg/L
Clinically-relevant alcohol or drug abuse within 12 months of screening
Known hypersensitivity to Interferons
Current or planned participation in an investigational new drug (IND) trial from 30-days prior to randomization through Day 14 post treatment
Intervention: Trospium
Trial phase: Phase 2
ATC code: A03DA06 | G04BD09
SMILES: [H][C@]12CC[C@]([H])(C[C@H](OC(=O)C(O)(c3ccccc3)c3ccccc3)C1)[N+]21CCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Subcutaneous injection of saline placebo

Pegylated interferon lambda: 180 mcg subcutaneous injection of pegylated interferon lambda
Eligibility criteria:
Inclusion Criteria:

Able to provide informed consent
Confirmed COVID-19 diagnosis based on PCR analysis of respiratory secretions
Positive SARS-CoV-2 RT-PCR test must be within 48 hours of randomization

Exclusion Criteria:

Clinically-significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol
Treatment with IFN or other immunomodulatory/immunosuppressive agent within 12 months before screening.
Respiratory compromise requiring ventilatory support other than nasal cannula (mask, bipap or intubation and mechanical ventilation)
History of treatment with any of the following medications within five half-lives or 30 days before administration of the study drug (whichever is longer): anti-IL-6, anti-IL6R antagonists, Janus kinase inhibitors, ustekinumab (anti-IL-12/23), or anti IL-23 agents (guselkumab).
Life threatening SAE during the screening period
Pregnant or Nursing Females
Platelet count <90,000 cells/mm3
WBC count <3,000 cells/mm3
ANC <1,500 cells/mm3
Hb <11 g/dL for women and <12 g/dL for men
CrCl < 50 mL/min
Bilirubin level ≥ 1.5x ULN
INR ≥1.5 (except in the setting of concomitant anticoagulant use)
CRP > 200 mg/L
Clinically-relevant alcohol or drug abuse within 12 months of screening
Known hypersensitivity to Interferons
Current or planned participation in an investigational new drug (IND) trial from 30-days prior to randomization through Day 14 post treatment
Intervention: ASCORBIC ACID
Trial phase: Phase 2
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: L-Ascorbic Acid (Vitamin C), intravenous infusion

L-ascorbic acid: 50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
Eligibility criteria:
Inclusion Criteria:

Adults of 18 years or older
Patients hospitalized with a diagnosis of COVID-19 based on central laboratory-confirmed COVID-19 Novel Coronavirus Disease-2019, based on a positive SARS-CoV-2 RT-PCR confirmed within 72 hours prior to enrollment of nasal, oropharyngeal, or BAL specimen with hypoxemia, (i.e., decrease in oxygenation, as outlined below)
Pulse oximetry saturation (SpO2) < 93% on room air in WHO COVID-19 ordinal scale 3 patients, regardless the need for assisted ventilation, or oxygenation.
Any new requirement of supplemental oxygen, with any oxygen device (WHO COVID-19 ordinal scale 4-7, regardless of pulse oximetry reading)
In patients with supplemental oxygen at home, any increase in the requirement of supplemental oxygen.
In ICU level care

Exclusion Criteria:

Age less than 18 years
Known allergy to Vitamin C
Inability to obtain consent from patient or next of kin
Presence of diabetic ketoacidosis
ANY history of oxalate stones at any time
Patients with Kidney Disease Improving Global Outcomes (KDIGO), CKD stage 4 (eGFR < 30 ml/min, CKD stage 5 and end-stage renal disease on dialysis patients are excluded.
Patients with Acute Kidney Injury, stage 3.
Pregnant, or lactating
Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency
Patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine.
Patients with active sickle cell crisis
Prisoners
Patients outside ICU level care
Intervention: Desvenlafaxine
Trial phase: Phase 3
ATC code: N06AX23
SMILES: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 206
Group description: MD-120 50 mg, orally, once daily for up to Week 8
Eligibility criteria:
Inclusion Criteria:

Patient with diagnosis of Major Depressive Disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).
Hamilton Depression Rating Scale-17 (HAM-D17) total score of ≥20.

Exclusion Criteria:

Patient who meets DSM-5 criteria of the following disorders for current or past history.

Schizophrenia spectrum and other psychotic disorders Bipolar and related disorders Substance use disorders (exclusive of tobacco and caffeine)

Patient who had suicidal behavior in Columbia-Suicide Severity Rating Scale (C-SSRS) within 1 year before start of screening phase.
Intervention: Desvenlafaxine
Trial phase: Phase 3
ATC code: N06AX23
SMILES: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 204
Group description: MD-120 50 mg, orally, once daily for up to Week 1, followed by MD-120 100 mg, orally, once daily for up to Week 8
Eligibility criteria:
Inclusion Criteria:

Patient with diagnosis of Major Depressive Disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).
Hamilton Depression Rating Scale-17 (HAM-D17) total score of ≥20.

Exclusion Criteria:

Patient who meets DSM-5 criteria of the following disorders for current or past history.

Schizophrenia spectrum and other psychotic disorders Bipolar and related disorders Substance use disorders (exclusive of tobacco and caffeine)

Patient who had suicidal behavior in Columbia-Suicide Severity Rating Scale (C-SSRS) within 1 year before start of screening phase.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 1 | Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Participants administer 2 sprays of isotonic saline (0.9% NaCl) to each nare via nasal spray bottle, four times a day for 5 days.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of COVID-19 by lab test within 5 days of study participation

Exclusion Criteria:

Allergy to "iodine," shellfish, or food dye
Receiving intranasal steroids
Sinus surgery within 30 days of beginning the study
Intubated at the time of enrollment
Pregnancy
Participation in other COVID-19 studies - to be determined on a case by case basis
Intervention: Methylphenidate
Trial phase: Phase 4
ATC code: N06BA04 | N06BA11 | N06BA15
SMILES: COC(=O)C(c1ccccc1)C1CCCCN1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 35
Group description: Participants received a single, low dose of methylphenidate (0.3 mg/kg) before MRI scan
Eligibility criteria:
Inclusion Criteria:

Between 8-12 years old
Diagnosis of ADHD (for ADHD group); ADHD group only can have comorbid Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses of oppositional defiant disorder, conduct disorder, depressive disorders, or anxiety disorders
ADHD subjects must never have been treated with medication for their ADHD

Exclusion Criteria:

Wechsler Intelligence Scale for Children-Fifth Edition Full-Scale Intelligence Quotient (IQ) < 80
Wechsler Individual Achievement Test-Third Edition Word Reading < 85
Any neurologic or developmental disabilities
Any reading or learning disabilities
Visual impairment that cannot be corrected-to-normal
Color blindness
Documented hearing impairment greater than 25 decibels (dB) loss in either year
Have already gone through puberty (Tanner Stage II or higher)
Medical contraindication to MRI
Any psychoactive medication
Intervention: Dapagliflozin Propanediol
Trial phase: Phase 3
SMILES: CC(O)CO.CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1.O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 613
Group description: Dapagliflozin 10 mg daily

Dapagliflozin 10 MG: Active Comparator: Dapagliflozin 10mg
Eligibility criteria:
Inclusion Criteria:

Provision of informed consent
Male or female patients aged ≥18 years
Currently hospitalized
Hospital admission no more than 4 days prior to screening
Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by laboratory testing within 10 days prior to screening, or strongly suspected SARS-CoV-2 infection on presentation
Chest radiography or computerized tomography (CT) findings that, in the opinion of the investigator, are consistent with coronavirus disease 2019 (COVID-19)
Blood oxygen saturation (SpO2) ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less)

Medical history of at least one of the following:

hypertension
type 2 diabetes
atherosclerotic cardiovascular disease
heart failure (with either reduced or preserved left ventricular ejection fraction (LVEF))
chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate (eGFR) between 25 to 60 mL/min/1.73 m2)

Key Exclusion Criteria:

Respiratory decompensation requiring mechanical ventilation (includes invasive or non invasive ventilation, continuous positive airway pressure (CPAP), or bilevel positive airway pressure (BiPAP))
Expected need for mechanical ventilation (includes invasive or non-invasive ventilation, CPAP, or BiPAP) within the next 24 hours
Expected survival of less than 24 hours at the time of presentation, in the judgement of the investigator
eGFR <25 mL/min/1.73 m2 or receiving renal replacement therapy/dialysis
Systolic blood pressure <95 mmHg and/or requirement for vasopressor treatment and/or inotropic or mechanical circulatory support at Screening
History of type 1 diabetes mellitus
History of diabetic ketoacidosis
Currently receiving or has received in the last 14 days, experimental immune modulators and/or monoclonal antibody therapies for COVID-19
Current treatment with any sodium-glucose cotransporter-2 inhibitor (SGLT2i) (eg, dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) or having received treatment with any SGLT2i within 4 weeks prior to screening

Current participation in another interventional clinical trial (with an investigational drug) that is not an observational registry

Note that use of rescue therapies including immune modulators, monoclonal antibody therapies, antiviral therapies, and other agents that are approved or being used through open-label compassionate/expanded use programs or in accordance with the local standard of care is permitted during the study.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Patients with a Khorana risk score of 1 receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.

Aspirin: 81 mg aspirin daily
Eligibility criteria:
Inclusion Criteria:

Khorana score = 1
Over age 18
English-speaking female patients
Able to consent
Receiving neoadjuvant chemotherapy Cancer of primary ovarian, fallopian tube, mullerian, or peritoneal origin

Exclusion Criteria:

Allergy or intolerance to study medication
Indication for a non-aspirin form of antiplatelet (i.e. cardiac stent)
Already on alternative form of anticoagulation
Active bleeding
High risk for active bleeding (i.e. recent intracranial bleed or gastrointestinal bleed, known brain metastases)
Thrombocytopenia (platelets <50,000)
Unable to complete medication adherence diary
Unable to take oral medications
Intervention: Mitomycin
Trial phase: Phase 4
ATC code: L01DC03
SMILES: [H][C@]12N[C@@]1([H])CN1C3=C(C(=O)C(N)=C(C)C3=O)[C@@H](COC(N)=O)[C@]12OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: MMC delivered by preoperative subconjunctival injection

Mitomycin-C injection: MMC delivered by preoperative subconjunctival injection
Eligibility criteria:
Inclusion Criteria:

medically uncontrolled glaucoma
healthy and freely mobile conjunctiva in superior bulbar region

Exclusion Criteria:

previous incisional glaucoma surgery
no light perception vision
pregnant or nursing women
iris neovascularization or proliferative retinopathy
iridocorneal endothelial syndrome
chronic or recurrent uveitis
steroid-induced glaucoma
pathologic myopia or refractive error less than -6.00 diopters
unwillingness or inability to give consent
inability to return for scheduled protocol visits
Intervention: Naldemedine
Trial phase: Phase 2
ATC code: A06AH05
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CC(C(=O)NC(C)(C)c1nc(-c3ccccc3)no1)=C2O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants received 1.25 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
Eligibility criteria:
Inclusion Criteria:

Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:

partial small or large bowel resection with primary anastomosis
radical cystectomy requiring bowel transection with primary anastomosis

Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:

early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery
early ambulation, which is defined as ambulation on Day 1
early diet advancement on Day 1
Planned to receive primary postoperative pain management with opioid analgesia administered by any route.
American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).

Exclusion Criteria:

Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.
Scheduled for endoscopic or laparoscopic surgery.
Complete bowel obstruction.
Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).
More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.
Pregnancy or lactation.
Presence of peritoneal catheter (for example, for dialysis or chemotherapy).
Intervention: Naldemedine
Trial phase: Phase 2
ATC code: A06AH05
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CC(C(=O)NC(C)(C)c1nc(-c3ccccc3)no1)=C2O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants received 2.5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
Eligibility criteria:
Inclusion Criteria:

Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:

partial small or large bowel resection with primary anastomosis
radical cystectomy requiring bowel transection with primary anastomosis

Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:

early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery
early ambulation, which is defined as ambulation on Day 1
early diet advancement on Day 1
Planned to receive primary postoperative pain management with opioid analgesia administered by any route.
American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).

Exclusion Criteria:

Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.
Scheduled for endoscopic or laparoscopic surgery.
Complete bowel obstruction.
Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).
More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.
Pregnancy or lactation.
Presence of peritoneal catheter (for example, for dialysis or chemotherapy).
Intervention: Naldemedine
Trial phase: Phase 2
ATC code: A06AH05
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CC(C(=O)NC(C)(C)c1nc(-c3ccccc3)no1)=C2O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants received 5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
Eligibility criteria:
Inclusion Criteria:

Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:

partial small or large bowel resection with primary anastomosis
radical cystectomy requiring bowel transection with primary anastomosis

Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:

early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery
early ambulation, which is defined as ambulation on Day 1
early diet advancement on Day 1
Planned to receive primary postoperative pain management with opioid analgesia administered by any route.
American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).

Exclusion Criteria:

Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.
Scheduled for endoscopic or laparoscopic surgery.
Complete bowel obstruction.
Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).
More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.
Pregnancy or lactation.
Presence of peritoneal catheter (for example, for dialysis or chemotherapy).
Intervention: Etoposide
Trial phase: Phase 2
ATC code: L01CB01
SMILES: COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4

Etoposide: Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
Eligibility criteria:
Inclusion Criteria:

Confirmed COVID-19 infection

Evidence of cytokine storm defined as:

Peak ferritin > 10,000 ng/mL OR
Peak ferritin > 500 ng/mL and one or more of the following at any time during hospital admission: Lactate dehydrogenase > 500 U/L, d-dimer >1000 ng/mL, C-reactive protein > 100 mg/L, or white blood count> 15 k/microlitre

Cohort 1: Intubated status as a result of COVID infection-associated respiratory illness.

Exclusion Criteria:

Pregnancy or breastfeeding
History of severe hypersensitivity to etoposide products
Absolute neutrophil count (ANC) < 1000 cells/mm3
Platelet count <50,000/mm3
Bilirubin > 3.0 mg/dL
Aspartate OR alanine aminotransferase > 5.0 x upper limit of normal
Creatinine Clearance < 15 mL/min (calculated by Cockcroft Fault formula)
Requiring continuous renal replacement therapy
Requiring >1 vasopressor
Requiring extracorporeal membrane oxygenation (ECMO)
Other active, life-threatening infections
Anti-cytokine treatment (including anakinra or Interleukin 6 antibodies eg tocilizumab, sarilumab) administration within three half-lives of the medication used
Hydroxychloroquine, colchicine, azithromycin, doxycycline-if administered for COVID infection-must be discontinued for at least 24 hours prior to randomization.
Has a history or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with subject participation, or is not in the best interest of the patient to participate, in the opinion of the investigator.
Inability to consent and no legally authorized representative
Poorly controlled HIV infection (CD4 count <100 cells/mm3)